Covalent arylation of metallothionein by oxidized dopamine products: A possible mechanism for zinc-mediated enhancement of dopaminergic neuron survival

Neurotoxicity Research

Volumn 14, Issue 4, 2008, Pages 317-328

  Gauthier, Michelle A ^a   Eibl, Joseph K ^a   Crispo, James A G ^a   Ross, Gregory M ^a  

^a NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

6 Hydroxydopamine; BDNF; Catecholamine; Oxidative stress; Parkinson's disease

Indexed keywords

DOPAMINE; DOPAMINE DERIVATIVE; METALLOTHIONEIN; OXIDOPAMINE; ZINC ION; ZINC;

ANIMAL CELL; ARTICLE; ARYLATION; CELL COUNT; CELL SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; COVALENT BOND; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; EMBRYO; FEMALE; HOMEOSTASIS; IN VITRO STUDY; NERVE CELL CULTURE; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; CULTURE TECHNIQUE; CYTOLOGY; DRUG EFFECT; GENETICS; METABOLISM; NERVE CELL; OXIDATION REDUCTION REACTION; PHYSIOLOGY; RABBIT; UPREGULATION;

ANIMALS; CELL CULTURE TECHNIQUES; CELL SURVIVAL; DOPAMINE; METALLOTHIONEIN; NEURONS; OXIDATION-REDUCTION; OXIDOPAMINE; RABBITS; RATS; UP-REGULATION; ZINC;

EID: 62749195248     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033856     Document Type: Article

References (39)

1. Ambjorn M, Asmussen JW, Lindstam M, Gotfryd K, Jacobsen C, Kiselyov VV, Moestrup SK, Penkowa M, Bock E and Berezin V (2008) Metallothionein and a peptide modeled after metallothionein, EmtinB, induce neuronal differentiation and survival through binding to receptors of the low-density lipoprotein receptor family. J. Neurochem. 104(1), 21-37.
2. Andrews GK (2000) Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochem. Pharmacol. 59(1), 95-104.
3. Asanuma M, Miyazaki I, Higashi Y, Tanaka K, Haque ME, Fujita N and Ogawa N (2002) Aggravation of 6-hydroxydo-pamine-induced dopaminergic lesions in metallothionein-I and -II knock-out mouse brain. Neurosci. Lett. 327(1), 61-65.
4. Aschner M (1998) Metallothionein (MT) isoforms in the central nervous system (CNS): Regional and cell-specific distribution and potential functions as an antioxidant. Neurotoxicology 19(4-5), 653-660.
5. Aschner M, Cherian MG, Klaassen CD, Palmiter RD, Erickson JC and Bush AI (1997) Metallothioneins in brain - the role in physiology and pathology. Toxicol. Appl. Pharmacol. 142(2), 229-242.
6. Bertoni-Freddari C, Mocchegiani E, Malavolta M, Casoli T, Di Stefano G and Fattoretti P (2006) Synaptic and mitochon-drial physiopathologic changes in the aging nervous system and the role of zinc ion homeostasis. Mech. Ageing Dev. 127(6), 590-596.
7. Chen WQ, Cheng YY, Zhao XL, Li ST, Hou Y and Hong Y (2006) Effects of zinc on the induction of metallothionein isoforms in hippocampus in stress rats. Exp. Biol. Med. (Maywood) 231(9), 1564-1568.
8. Cajungco MP and Lees GJ (1997) Zinc metabolism in the brain: Relevance to human neurodegenerative disorders. Neurobiol. Dis. 4(3-4), 137-169.
9. Dryhurst G (2001) Are dopamine, norepinephrine, and serotonin precursors of biologically reactive intermediates involved in the pathogenesis of neurodegenerative brain disorders? Adv. Exp. Med. Biol. 500, 373-396.
10. Ebadi M (1991) Metallothioneins and other zinc-binding proteins in brain. Methods Enzymol. 205, 363-387.
11. Ebadi M, Leuschen MP, el Refaey H, Hamada FM and Rojas P (1996) The antioxidant properties of zinc and metallothionein. Neurochem. Int. 29(2), 159-166.
12. Ebadi M, Sharma S, Muralikrishnan D, Shavali S, Eken J, Sangchot P, Chetsawang B and Brekke L (2002) Metallothionein provides ubiquinone-mediated neuroprotection in Parkinson's disease. Proc. West. Pharmacol. Soc. 45, 36-38.
13. Ebadi M and Sharma S (2006) Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. Exp. Biol. Med. (Maywood) 231(9), 1576-1583.
14. Erickson JC, Hollopeter G, Thomas SA, Froelick GJ and Palmiter RD (1997) Disruption of the metallothionein-III gene in mice: Analysis of brain zinc, behavior, and neuron vulnerability to metals, aging, and seizures. J. Neurosci. 17(4), 1271-1281.
15. Frederickson CJ, Klitenick MA, Manton WI and Kirkpatrick JB (1983) Cytoarchitectonic distribution of zinc in the hippocampus of man and the rat. Brain Res. 273(2), 335-339.
16. Garrett SH, Phillips V, Somji S, Sens MA, Dutta R, Park S, Kim D and Sens DA (2002) Transient induction of metallothionein isoform 3 (MT-3), c-fos, c-jun and c-myc in human proximal tubule cells exposed to cadmium. Toxicol. Lett. 126(1), 69-80.
17. Haq F, Mahoney M and Koropatnick J (2003) Signaling events for metallothionein induction. Mutat. Res. 533(1-2), 211-226.
18. Hidalgo J, Garcia A, Oliva AM, Giralt M, Gasull T, Gonzalez B, Milnerowicz H, Wood A and Bremner I (1994) Effect of zinc, copper and glucocorticoids on metallothionein levels of cultured neurons and astrocytes from rat brain. Chem. Biol. Interact. 93(3), 197-219.
19. Jiang H, Ren Y, Zhao J and Feng J (2004) Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum. Mol. Genet. 13(16), 1745-1754.
20. 2+ entry produces oxidative neuronal necrosis in cortical cell cultures. Eur. J. Neurosci. 11 (1), 327-334.
21. Krezel A, Hao Q and Maret W (2007) The zinc/thiolate redox biochemistry of metallothionein and the control of zinc ion fluctuations in cell signaling. Arch. Biochem. Biophys. 463(2), 188-200.
22. 2+ on the induction of PC12 cell death and dopamine depletion in the striatum: Possible implication in the pathogenesis of Parkinson's disease. Neurobiol. Dis. 17(1), 54-61.
23. Maret W (2006) Zinc coordination environments in proteins as redox sensors and signal transducers. Antioxid. Redox. Signal 8(9-10), 1419-1441.
24. Mendez-Alvarez E, Soto-Otero R, Hermida-Ameijeiras A, Lopez-Real AM and Labandeira-Garcia JL (2002) Effects of aluminum and zinc on the oxidative stress caused by 6-hydroxydopamine autoxidation: Relevance for the pathogenesis of Parkinson's disease. Biochim. Biophys. Acta 1586(2), 155-168.
25. Miyazaki I, Asanuma M, Hozumi H, Miyoshi K and Sogawa N (2007) Protective effects of metallothionein against dopamine quinone-induced dopaminergic neurotoxicity. FEBS Lett. 581(25), 5003-5008.
26. Nair VD and Mishra RK (2001) Molecular cloning, localization and characterization of a 40-kDa catecholamine-regulated protein. J. Neurochem. 76(4), 1142-1152.
27. Palmiter RD (1994) Regulation of metallothionein genes by heavy metals appears to be mediated by a zinc-sensitive inhibitor that interacts with a constitutively active transcription factor, MTF-1. Proc. Natl. Acad. Sci. USA 91(4), 1219-1223.
28. Pardo B, Paino CL, Casarejos MJ and Mena MA (1997) Neuronal-enriched cultures from embryonic rat ventral mes-encephalon for pharmacological studies of dopamine neurons. Brain Res. Brain Res. Protoc. 1(2), 127-132.
29. Post JI, JK Eibl and GM Ross (2008) Zinc induces motor neuron death via a selective inhibition of brain-derived neu-rotrophic factor activity. Amyotroph. Lateral Scler. 9(3), 149-155.
30. Rabinovic AD and Hastings TG (1998) Role of endogenous glutathione in the oxidation of dopamine. J. Neurochem. 71(5), 2071-2078.
31. Rabinovic AD, Lewis DA and Hastings TG (2000) Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience 101(1), 67-76.
32. Ross GM, McCarry BE, Thakur S and Mishra RK (1993) Identification of novel catecholamine absorbing proteins in the central nervous system. J. Mol. Neurosci. 4(3), 141-148.
33. Ross GM, Shamovsky IL, Lawrance G, Solc M, Dostaler SM, Jimmo SL, Weaver DF and Riopelle RJ (1997) Zinc alters conformation and inhibits biological activities of nerve growth factor and related neurotrophins. Nat. Med. 3(8), 872-878.
34. Saito Y, Nishio K, Ogawa Y, Kinumi T, Yoshida Y, Masuo Y and Niki E (2007) Molecular mechanisms of 6-hydroxydop-amine-induced cytotoxicity in PC12 cells: Involvement of hydrogen peroxide-dependent and-independent action. Free Radic. Biol. Med. 42(5), 675-685.
35. Shiraga H, Pfeiffer RF and Ebadi M (1993) The effects of 6-hydroxydopamine and oxidative stress on the level of brain metallothionein. Neurochem. Int. 23(6), 561-566.
36. Stankovic RK, Chung RS and Penkowa M (2007) Metallothioneins I and II: neuroprotective significance during CNS pathology. Int. J. Biochem. Cell. Biol. 39(3), 484-489.
37. Thomas MP, Chartrand K, Reynolds A, Vitvitsky V, Banerjee R and Gendelman HE (2007) Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: Relevance for the pathogenesis of Parkinson's disease. J. Neurochem. 100(2), 503-519.
38. Vali S, Mythri RB, Jagatha B, Padiadpu J, Ramanujan KS, Andersen JK, Gorin F and Bharath MM (2007) Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: A dynamic model. Neuroscience 149(4), 917-930. Epub 2007 Sep 12.
39. Xu J, Kao SY, Lee FJ, Song W, Jin LW and Yankner BA (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8(6), 600-606.